Next Article in Journal
Cutaneous Alternariosis Caused by Alternaria infectoria: Three Cases in Kidney Transplant Patients
Previous Article in Journal
B-Mode Ultrasound Imaging, Doppler Imaging, and Real-Time Elastography in Cutaneous Malignant Melanoma and Lymph Node Metastases
Healthcare 2013, 1(1), 96-99; doi:10.3390/healthcare1010096
Case Report

Scalp In-Transit Metastatic Melanoma Treated with Interleukin-2 and Pulsed Dye Laser

 and *
Received: 20 August 2013 / Revised: 16 October 2013 / Accepted: 21 October 2013 / Published: 25 October 2013
View Full-Text   |   Download PDF [593 KB, uploaded 25 October 2013]   |   Browse Figure
Abstract: No particular regimen is considered standard therapy for widespread metastatic melanoma, although surgery is the primary choice for regional nodal metastases. Systemic interleukin-2 (IL-2) is an effective immunotherapy for melanoma, but standard doses are associated with severe toxicity. We report a patient who was treated with intralesional low-dose IL-2 and V-beam pulsed dye laser for the treatment of scalp melanoma metastases. This treatment resulted in rapid regression of metastatic tumors with limited adverse effects.
Keywords: interleukin-2; melanoma; pulsed dye laser therapy interleukin-2; melanoma; pulsed dye laser therapy
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Wang, M.Z.; Brewer, J.D. Scalp In-Transit Metastatic Melanoma Treated with Interleukin-2 and Pulsed Dye Laser. Healthcare 2013, 1, 96-99.

AMA Style

Wang MZ, Brewer JD. Scalp In-Transit Metastatic Melanoma Treated with Interleukin-2 and Pulsed Dye Laser. Healthcare. 2013; 1(1):96-99.

Chicago/Turabian Style

Wang, Michael Z.; Brewer, Jerry D. 2013. "Scalp In-Transit Metastatic Melanoma Treated with Interleukin-2 and Pulsed Dye Laser." Healthcare 1, no. 1: 96-99.


Healthcare EISSN 2227-9032 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
{"cc_re__cc_re__cc_by_3_0": ["ukin-2 and Pulsed Dye Laser\">\n\n            <meta name=\"dc.creator\" content=\"Michael Wang\">\n            <meta name=\"dc.creator\" content=\"Jerry Brewer\">\n    \n    <meta name=\"dc.type\" content=\"Case Report\">\n    <meta name=\"dc.source\" content=\"Healthcare 2013, Vol. 1, Pages 96-99\">\n    <meta name=\"dc.date\" content=\"2013-10-25\">\n            <meta name =\"dc.identifier\" content=\"10.3390/healthcare1010096\">\n    \n    <meta name=\"dc.publisher\" content=\"Multidisciplinary Digital Publishing Institute\">\n    <meta name=\"dc.rights\" content=\"http://creativecommons.org/licenses/by/3.0/\">\n    <meta name=\"dc.format\" content=\"application/pdf\" >\n    <meta name=\"dc.language\" content=\"en\" >\n\t<meta name=\"dc.description\" content=\"No particular regimen is considered standard therapy for widespread metastatic melanoma, although surgery is the primary choice for regional nodal metastases. Systemic interleukin-2 (IL-2) is an effective immunotherapy for melanoma, but standard doses are associated with severe toxicity. We report a patient who was treated with intralesional  low-dose IL-2 and", "n class=\"prepos\">Keywords: </span>\n\t\t  \t<span itemprop=\"keywords\" style=\"display:none\">interleukin-2; melanoma; pulsed dye laser therapy</span>\t\t  \t<span>\t\t\t  \t\t<a href=\"/search?q=interleukin-2\">interleukin-2</a>;\t\t\t  \t\t<a href=\"/search?q=melanoma\">melanoma</a>;\t\t\t  \t\t<a href=\"/search?q=pulsed dye laser therapy\">pulsed dye laser therapy</a></span>\n\t\t  </div>\n\t\t\n\n\t\t\n\t\t<div class=\"licenseText\" style=\"padding: 1em; text-align: justify;\">\n\t\t\t\t<em>This is an open access article distributed under the <a href=\"http://creativecommons.org/licenses/by/3.0/\" target=\"_blank\">\n\t\tCreative Commons Attribution License</a> which permits unrestricted use, distribution,\n\t\tand reproduction in any medium, provided the original work is properly cited.</em>\n\t\t\t\t</div>\n\n   </div><div id=\"tabs-1\" class=\"ui-tabs-panel\">\n<div id=\"loaded\" style=\"display:none\">No</div><div id=framed_div style=\"display: none\"></div>\n  </div>\n\n  <div id=\"tabs-2\" class=\"ui-tabs-panel\">\n\t\t\t      <div id=\"article_stats_div\" style=\"text-align: center; display: none; border: solid #CCCCCC 1px\"><div id=\"art"], "copyright__copyright__copyright": ["th Interleukin-2 and Pulsed Dye Laser. Healthcare 2013, 1, 96-99.\n\nAMA Style\n\nWang MZ, Brewer JD. Scalp In-Transit Metastatic Melanoma Treated with Interleukin-2 and Pulsed Dye Laser. Healthcare. 2013; 1(1):96-99.\n\nChicago/Turabian Style\n\nWang, Michael Z.; Brewer, Jerry D. 2013. \"Scalp In-Transit Metastatic Melanoma Treated with Interleukin-2 and Pulsed Dye Laser.\" Healthcare 1, no. 1: 96-99.\n\n\nHealthcare EISSN 2227-9032 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert"]}